Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Apoptotic extracellular vesicles from peripancreatic adipose-derived mesenchymal stem cells ameliorate severe acute pancreatitis through the transcription factor EB-mediated autophagy-lysosomal pathway: an experimental s

Wang A., An Y., Wang X., Gou W., Xu F., Li Y.

Animal Study on Systemic / IV, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Surg (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41403290
PMCID
PMC13105693
DOI
10.1097/JS9.0000000000004555
Citations
1

Abstract (original English)

Background Mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have remarkable potential in alleviating the severity of pancreatic inflammation. However, most transplanted MSCs undergo apoptosis shortly after in vivo administration, producing apoptotic EVs (ApoEVs). Our study investigated the potential role and molecular mechanisms of ApoEVs derived from apoptotic MSCs in ameliorating severe acute pancreatitis (SAP). Methods DiO-labeled peripancreatic adipose-derived stem cells (P-ADSCs) were administered to rats with SAP to monitor P-ADSC apoptosis. ApoEVs were isolated from P-ADSCs subjected to apoptosis induction, and conventional EVs were obtained from untreated P-ADSCs. The morphology, size distribution and marker protein expression of ApoEVs and EVs were characterized, and functional differences were assessed via transcriptomic and proteomic analyses to compare their gene and protein compositions. The rat pancreatic acinar cell (PAC) line AR42J was used to assess cellular responses to ApoEVs, and an SAP rat model was used to compare the therapeutic efficacy of ApoEVs in ameliorating SAP. Specific inhibitors and small interfering RNA were used to perform loss-of-function assays. Results P-ADSCs underwent apoptosis in the pancreas within 72 h after being injected into rats with SAP. Notably, ApoEVs exhibited superior therapeutic effects in ameliorating SAP

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research